Scarica l'app Stockscreener
2.86
1.06%
0.03
Dopo l'orario di chiusura:
2.85
-0.010
-0.35%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché BLRX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.83
Aprire:
$2.74
Volume 24 ore:
9,965
Relative Volume:
0.49
Capitalizzazione di mercato:
$12.44M
Reddito:
$12.84M
Utile/perdita netta:
$-3.12M
Rapporto P/E:
-2.0833
EPS:
-1.3728
Flusso di cassa netto:
$-13.51M
1 W Prestazione:
-1.38%
1M Prestazione:
-4.98%
6M Prestazione:
-23.73%
1 anno Prestazione:
-14.63%
Intervallo 1D:
$2.70
$3.0199
Intervallo di 1 settimana:
$2.70
$3.0199
Portata 52W:
$2.3001
$7.7699
Bioline Rx Ltd Adr Stock (BLRX) Company Profile
Nome
Bioline Rx Ltd Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare BLRX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BLRX
Bioline Rx Ltd Adr
|
2.86 | 12.31M | 12.84M | -3.12M | -13.51M | -1.3728 |
|
VRTX
Vertex Pharmaceuticals Inc
|
486.03 | 126.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.81 | 82.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
756.76 | 47.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.07 | 44.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
314.36 | 35.08B | 4.98B | 69.60M | 525.67M | 0.5198 |
Bioline Rx Ltd Adr Stock (BLRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2017-05-18 | Aggiornamento | Maxim Group | Hold → Buy |
| 2017-02-13 | Iniziato | Rodman & Renshaw | Buy |
| 2016-08-12 | Downgrade | Maxim Group | Buy → Hold |
| 2015-08-17 | Reiterato | Maxim Group | Buy |
| 2015-07-27 | Reiterato | ROTH Capital | Buy |
| 2015-06-22 | Iniziato | JMP Securities | Mkt Outperform |
Mostra tutto
Bioline Rx Ltd Adr Borsa (BLRX) Ultime notizie
BioLineRx Wins Arbitration Ruling in Motixafortide Licensing Dispute - TipRanks
Analysts Offer Insights on Healthcare Companies: Harrow Health (HROW), Icon (ICLR) and Perspective Therapeutics (CATX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Solventum Corporation (SOLV) and Praxis Precision Medicines (PRAX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Travere Therapeutics (TVTX) and Beyond Air (XAIR) - The Globe and Mail
Analysts Conflicted on These Healthcare Names: MBX Biosciences, Inc. (MBX), Praxis Precision Medicines (PRAX) and Iovance Biotherapeutics (IOVA) - The Globe and Mail
BioLineRx Earnings Call: Strategic Initiatives Amid Revenue Challenges - MSN
BioLineRx Reports Q3 2025 Results and Strategic Expansion - TipRanks
Earnings call transcript: BioLineRx Q3 2025 earnings reveal significant revenue miss By Investing.com - Investing.com South Africa
BioLineRx Announces Q3 2025 Financial Results and New Joint Venture - TipRanks
Earnings call transcript: BioLineRx Q3 2025 earnings reveal significant revenue miss - Investing.com India
BioLineRx shares rise over 7% on better-than-expected earnings By Investing.com - Investing.com South Africa
BioLineRx shares rise over 7% on better-than-expected earnings - Investing.com
BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Finviz
BioLine Rx's Earnings: A Preview - Sahm
BioLineRx stock rises after partner receives key patent allowance By Investing.com - Investing.com India
BioLineRx stock rises after partner receives key patent allowance - Investing.com
BioLineRx to Report Third Quarter 2025 Results on November 24, 2025 - Finviz
BioLineRx stock rises after securing key patent for cancer treatment - Investing.com India
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types - Finviz
BioLineRx Secures USPTO Patent Allowance for Cancer Treatment with GLIX1 - TipRanks
BioLineRx receives key patent for cancer treatment GLIX1 - Investing.com India
BioLineRx receives key patent for cancer treatment GLIX1 By Investing.com - Investing.com South Africa
Analysts’ Top Healthcare Picks: Serina Therapeutics (SER), Cybin (CYBN) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB) and Autolus Therapeutics (AUTL) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Beyond Air (XAIR), Diamedica Therapeutics (DMAC) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Schrodinger (SDGR), Lexicon Pharmaceuticals (LXRX) and Cullinan Management (CGEM) - The Globe and Mail
Working capital per share of BioLineRX Ltd. Sponsored ADR – SWB:YP2 - TradingView
BioLineRx ADR Earnings Call: Optimism Amid Challenges - MSN
Analysts Are Bullish on Top Healthcare Stocks: Abbott Laboratories (ABT), Achieve Life Sciences (ACHV) - The Globe and Mail
Cash per share of BioLineRX Ltd. Sponsored ADR – FWB:YP2 - TradingView
BioLineRx, Hemispherian AS establish joint venture to develop GLIX1 - TipRanks
BioLineRx and Hemispherian Launch Joint Venture to Develop GLIX1 for Glioblastoma - TipRanks
BioLineRx and Hemispherian form joint venture to develop brain cancer drug - Investing.com
BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers - Sahm
BioLineRx (NASDAQ:BLRX) Stock Passes Above Two Hundred Day Moving Average – What’s Next? - Defense World
Analysts Offer Insights on Healthcare Companies: Intensity Therapeutics, Inc. (INTS), AnaptysBio (ANAB) and Adlai Nortye Ltd. Sponsored ADR (ANL) - The Globe and Mail
Earnings call transcript: BioLineRx Q2 2025 sees restructuring and innovation - Investing.com
BioLineRx: Strategic Pipeline Expansion and Strong Financial Health Justify Buy Rating - TipRanks
Options Volatility and Implied Earnings Moves Today, August 14, 2025 - TipRanks
Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (AVTX), Iovance Biotherapeutics (IOVA) and NextCure (NXTC) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: NextCure (NXTC), Lexaria Bioscience (LEXX) and Travere Therapeutics (TVTX) - The Globe and Mail
H.C. Wainwright Reaffirms Buy on BioLineRx Ltd. (BLRX) After ASCO 2025 - Finviz
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
BioLineRx upgraded to Buy from Hold at JonesResearch - Yahoo Finance
BioLineRx reports promising pancreatic cancer trial data - Investing.com
H.C. Wainwright Maintains Buy Rating, $26 Target on BioLineRx Stock - Investing.com
BioLineRx Reports Q1 2025 Financial Results and Strategic Updates - TipRanks
Analysts Are Bullish on These Healthcare Stocks: Korro Bio (KRRO), Perspective Therapeutics (CATX) - The Globe and Mail
BLRX stock touches 52-week low at $2.85 amid sharp annual decline - Investing.com
BioLineRx Reports Strong 2024 Financial Results and Strategic Advancements - TipRanks
BioLineRx to Report 2024 Annual Results on March 31, 2025 - Sahm
Bioline Rx Ltd Adr Azioni (BLRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.90%
2.73%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):